172 related articles for article (PubMed ID: 34095627)
1. Platinum-crosslinking polymeric nanoparticle for synergetic chemoradiotherapy of nasopharyngeal carcinoma.
Ding Y; Xiao X; Zeng L; Shang Q; Jiang W; Xiong S; Duan X; Shen J; Wang R; Guo J; Pan Y
Bioact Mater; 2021 Dec; 6(12):4707-4716. PubMed ID: 34095627
[TBL] [Abstract][Full Text] [Related]
2. Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma.
Zhu F; Wu Y; Wang H
Front Oncol; 2023; 13():1259331. PubMed ID: 37860184
[TBL] [Abstract][Full Text] [Related]
3. Lipid-Polymer Hybrid Nanoparticle-Based Combination Treatment with Cisplatin and EGFR/HER2 Receptor-Targeting Afatinib to Enhance the Treatment of Nasopharyngeal Carcinoma.
Fu D; Li C; Huang Y
Onco Targets Ther; 2021; 14():2449-2461. PubMed ID: 33859480
[TBL] [Abstract][Full Text] [Related]
4. O(6) -methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma.
Chen SH; Kuo CC; Li CF; Cheung CH; Tsou TC; Chiang HC; Yang YN; Chang SL; Lin LC; Pan HY; Chang KY; Chang JY
Int J Cancer; 2015 Sep; 137(6):1291-305. PubMed ID: 25693518
[TBL] [Abstract][Full Text] [Related]
5. GSH triggered intracellular aggregated-cisplatin-loaded iron oxide nanoparticles for overcoming cisplatin resistance in nasopharyngeal carcinoma.
Bejjanki NK; Xu H; Xie M
J Biomater Appl; 2021 Jul; 36(1):45-54. PubMed ID: 33402041
[TBL] [Abstract][Full Text] [Related]
6. Preparation of FA-targeted magnetic nanocomposites co-loading TFPI-2 plasmid and cis-platinum and its targeted therapy effects on nasopharyngeal carcinoma.
Liu F; Chen B; Chen W; Chen S; Ma D; Xie M
Int J Med Sci; 2021; 18(11):2355-2365. PubMed ID: 33967612
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of β-Catenin Decreases the Radiosensitivity of Human Nasopharyngeal Carcinoma CNE-2 Cells.
He H; Lin K; Su Y; Lin S; Zou C; Pan J; Zhou Y; Chen C
Cell Physiol Biochem; 2018; 50(5):1929-1944. PubMed ID: 30396174
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
[TBL] [Abstract][Full Text] [Related]
9. Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma.
Komatsu M; Tsukuda M; Matsuda H; Horiuchi C; Taguch T; Takahashi M; Nishimura G; Mori M; Niho T; Ishitoya J; Sakuma Y; Hirama M; Shiono O
Anticancer Res; 2012 Feb; 32(2):681-6. PubMed ID: 22287763
[TBL] [Abstract][Full Text] [Related]
10. High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy.
Fu X; Hu J; Han HY; Hua YJ; Zhou L; Shuai WD; Du WY; Kuang CM; Chen S; Huang W; Liu RY
Oncotarget; 2015 Sep; 6(29):28478-90. PubMed ID: 26156020
[TBL] [Abstract][Full Text] [Related]
11. Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy.
Oliva M; Huang SH; Taylor R; Su J; Xu W; Hansen AR; Jang R; Bayley A; Hosni A; Giuliani M; Ringash J; Bratman SV; Cho J; Irish J; Waldron J; Weinreb I; Kim J; O'Sullivan B; Siu LL; Spreafico A
Oral Oncol; 2020 Jun; 105():104666. PubMed ID: 32272384
[TBL] [Abstract][Full Text] [Related]
12. Self-targeting platinum(IV) amphiphilic prodrug nano-assembly as radiosensitizer for synergistic and safe chemoradiotherapy of hepatocellular carcinoma.
Xiao X; Wang Y; Chen J; Qin P; Chen P; Zhou D; Pan Y
Biomaterials; 2022 Oct; 289():121793. PubMed ID: 36126545
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma.
Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH
Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467
[TBL] [Abstract][Full Text] [Related]
14. TAT peptide-modified cisplatin-loaded iron oxide nanoparticles for reversing cisplatin-resistant nasopharyngeal carcinoma.
Weng H; Bejjanki NK; Zhang J; Miao X; Zhong Y; Li H; Xie H; Wang S; Li Q; Xie M
Biochem Biophys Res Commun; 2019 Apr; 511(3):597-603. PubMed ID: 30826059
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of NFBD1/MDC1 enhances chemosensitivity to cisplatin or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells.
Zeng Q; Wang Z; Liu C; Gong Z; Yang L; Jiang L; Ma Z; Qian Y; Yang Y; Kang H; Hong S; Bu Y; Hu G
Mol Cell Biochem; 2016 Jul; 418(1-2):137-46. PubMed ID: 27334757
[TBL] [Abstract][Full Text] [Related]
16. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H
BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452
[TBL] [Abstract][Full Text] [Related]
17. Curcumin loaded sub-30 nm targeting therapeutic lipid nanoparticles for synergistically blocking nasopharyngeal cancer growth and metastasis.
Luo H; Lu L; Liu N; Li Q; Yang X; Zhang Z
J Nanobiotechnology; 2021 Jul; 19(1):224. PubMed ID: 34320999
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
[TBL] [Abstract][Full Text] [Related]
19. Hypertrophic adenoids in patients with nasopharyngeal carcinoma: appearance at magnetic resonance imaging before and after treatment.
Wu YP; Cai PQ; Tian L; Xu JH; Mitteer RA; Fan Y; Zhang Z
Chin J Cancer; 2015 Mar; 34(3):130-6. PubMed ID: 25962737
[TBL] [Abstract][Full Text] [Related]
20. Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo.
Luo K; Guo W; Yu Y; Xu S; Zhou M; Xiang K; Niu K; Zhu X; Zhu G; An Z; Yu Q; Gan Z
J Control Release; 2020 Oct; 326():25-37. PubMed ID: 32531414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
